logo-loader

Medicus Pharma targets partnerships and clinical milestones as oncology pipeline advances

Published: 14:04 08 Oct 2026 BST

Medicus Pharma - Medicus Pharma targets partnerships and clinical milestones as oncology pipeline advances

Medicus Pharma (NASDAQ:MDCX) is positioning its precision oncology-led pipeline for a series of clinical and regulatory milestones, with partnerships and licensing deals central to the next phase of development, the company said in a shareholder update marking its third anniversary. 

The Nasdaq-listed biotech said its priorities are to advance selected clinical and regulatory milestones, align organizational costs with those priorities, and pursue licensing and co-development opportunities.  

Partnerships could contribute non-dilutive funding and expertise while reducing the capital Medicus would otherwise need to provide, though timing and terms remain uncertain. 

The portfolio is anchored by CD228V, an investigational antibody-drug conjugate that uses Pfizer's established vedotin linker-payload platform. Medicus plans to focus first on melanoma, particularly relapsed, refractory or immunotherapy-resistant disease, and to integrate biomarker work to better understand which patients may benefit.  

The company also sees potential in CD228-expressing lung, head and neck, and esophageal cancers. 

For SkinJect, the US Food and Drug Administration has authorized initiation of SKNJCT-005, a planned registrational study in patients with Gorlin syndrome, a rare autosomal dominant disease. The study follows completion of the Phase 2 SKNJCT-003 trial, which identified the 200-microgram dose for further development. 

In urology and women's health, Medicus is advancing Teverelix, a next-generation GnRH antagonist acquired through Antev in August 2025. Priorities include acute urinary retention relapse prevention and symptomatic endometriosis, alongside a partnership-led strategy in advanced prostate cancer.  

The company recently submitted an optimized registrational protocol for that indication, designed to give potential partners a clearer development plan, subject to FDA review. 

Medicus said it has raised approximately $90 million through equity and debt financing since its start, supporting clinical development, acquisitions and operations while retaining resources for ongoing needs. 

 

Medicus Pharma applies for FDA priority voucher to accelerate SkinJect’s...

Medicus Pharma CEO Dr Raza Bokhari joined Steve Darling from Proactive to announce that the company has formally submitted an FDA Commissioner’s National Priority Voucher (CNPV) application on behalf of its partner SkinJect, seeking expedited regulatory review for the Doxorubicin Microneedle...

on 1/12/25